|
Patient number
|
Age
|
ER (%)
|
PR (%)
|
HER2 (+/−)
|
Ki67 (%)
|
Grade
|
Tumor size
|
LN mets
|
Anti-hormonal therapy
|
|---|
|
1
|
62
|
95
|
70
|
−
|
5
|
1
|
pT1b
|
pN1a
|
−
|
|
2
|
58
|
95
|
95
|
−
|
10
|
2
|
T1b
|
N0
|
−
|
|
3
|
50
|
100
|
100
|
+
|
5
|
1
|
pT1
|
pN0
|
Tamoxifen
|
|
4
|
73
|
95
|
2
|
−
|
25
|
2
|
pT2
|
pN1a
|
−
|
|
5
|
49
|
90
|
80
|
−
|
10
|
2
|
T1b
|
pN0
|
Tamoxifen
|
|
6
|
69
|
100
|
100
|
−
|
15
|
2
|
pT1a
|
pN0
|
Tamoxifen
|
|
7
|
53
|
95
|
60
|
−
|
10
|
2
|
pT1c
|
pN0
|
Letrozole
|
|
8
|
73
|
100
|
0
|
−
|
20
|
na
|
pT1c
|
pN0
|
Tamoxifen
|
|
9
|
67
|
90
|
80
|
−
|
5
|
1
|
pT1b
|
pN0
|
Tamoxifen
|
|
10
|
66
|
100
|
100
|
−
|
5
|
2
|
pT1c
|
pN0
|
Letrozole
|
|
11
|
64
|
95
|
80
|
−
|
10
|
1
|
pT1b
|
pN0
|
Letrozole
|
|
12
|
61
|
80
|
100
|
−
|
10
|
2
|
pT1b
|
pN0
|
Anastrozole
|
|
13
|
43
|
95
|
95
|
−
|
10
|
2
|
pT1c
|
pN0
|
Tamoxifen
|
- Patient’s demographics, tumor subtype, grade, stage (pT and pN), and anti-hormonal treatment after conservative surgery. ER (%), estrogen receptor expression in percent; PR (%), progesterone receptor expression in percent; HER2 (±), overexpression of HER-2; Ki67 (%), fraction of cancer cells positive for Ki67 expression
